

## UTILIZATION MANAGEMENT MEDICAL POLICY

**POLICY:** Oncology (Injectable) – Datroway Utilization Management Medical Policy

- Datroway® (datopotamab deruxtecan-dlnk intravenous infusion – Daiichi Sankyo)

**REVIEW DATE:** 01/29/2025

---

### OVERVIEW

Datroway, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, is indicated for the following:<sup>1</sup>

- **Breast cancer**, unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/ISH–) breast cancer in adults who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.

### Guidelines

The National Comprehensive Cancer Network (NCCN) breast cancer guidelines (version 1.2025 - January 31, 2025) has recommendations for the treatment of HR-positive, HER2-negative recurrent unresectable or Stage IV disease with visceral crisis or endocrine refractory.<sup>2</sup> For first-line therapy, in patients with no germline breast cancer (BRCA) mutation and/or IHC HER2 0+, 1+, or 2+/ISH negative, systemic chemotherapy is the “Preferred” option (category 1). Enhertu® (fam-trastuzumab deruxtecan-nxki IV infusion) is noted as an “Other Recommended Regimen” in the first-line setting (category 2A). For second-line therapy, Enhertu is “Preferred” for HER2 IHC 0+, 1+, or 2+/ISH negative disease (category 1). For patients who are not candidates for Enhertu, Trodelvy® (sacituzumab govitecan-hziy IV infusion) is “Preferred” (category 1); in this second-line setting, Datroway is noted as an “Other Recommended Regimen” (category 2A) for HER2 IHC 0, 1+, or 2+/ISH negative disease. In a footnote the guidelines state that Datroway did not meet the overall survival endpoint in the TROPION-Breast01 trial; however, previously approved ADCs such as Enhertu and Trodelvy have shown an overall benefit in randomized Phase III trials. It is also noted that the utility of using Datroway in patients with prior ADC treatment are not known since the pivotal study did not include patients who had previously received treatment with ADCs.

### POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Datroway. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indication. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of specialized skills required for evaluation and diagnosis of patients treated with Datroway as well as the monitoring required for adverse events and long-term efficacy, approval requires Datroway to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Datroway is recommended in those who meet the following criteria:

#### **FDA-Approved Indication**

---

**1. Breast Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, C, D, E, F, and G):

- A) Patient is  $\geq 18$  years of age; AND
- B) Patient has unresectable or metastatic disease; AND
- C) Patient has hormone receptor (HR)-positive disease; AND
- D) Patient has human epidermal growth factor receptor (HER2)-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization [ISH]-negative) disease; AND
- E) Patient has received prior endocrine-based therapy; AND  
Note: Examples of endocrine therapy are tamoxifen, anastrozole, letrozole, exemestane.
- F) Patient has received prior chemotherapy for unresectable or metastatic disease; AND  
Note: Examples are paclitaxel, doxorubicin, liposomal doxorubicin, gemcitabine, capecitabine, vinorelbine, Halaven (eribulin intravenous infusion), cyclophosphamide, docetaxel.
- G) The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve if each dose does not exceed 6 mg/kg (up to a maximum of 540 mg for patients  $\geq 90$  kg), administered as an intravenous infusion not more frequently than once every 3 weeks.

---

**CONDITIONS NOT RECOMMENDED FOR APPROVAL**

Coverage of Datroway is not recommended in the following situations:

- 1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**

- 1. Datroway® intravenous infusion [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo; January 2025.
- 2. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 1.2025 – January 31, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 20, 2025.

**HISTORY**

Type of Revision	Summary of Changes	Review Date
New Policy	--	01/29/2025
DEU Update	02/20/2025: updated guidelines to include Datroway.	--